Cataract surgery in setting of ocular surface disease.
Journal
Current opinion in ophthalmology
ISSN: 1531-7021
Titre abrégé: Curr Opin Ophthalmol
Pays: United States
ID NLM: 9011108
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
aheadofprint
Résumé
The purpose of this article is to review the available strategies to successfully identify and manage ocular surface disease (OSD) pre, intra and post-cataract surgery. Cataract surgery and OSD have an intricate relationship: the surgical procedure can induce or exaggerate OSD symptoms, while OSD can negatively impact surgical refractive outcomes and increase the rate of postoperative complications. Improving the health and stability ocular surface is the key to enhance post cataract surgery refractive outcomes and avoid complications. This is pivotal for patients affected by severe OSD, but is also important for patients with minimal signs or symptoms. A correct diagnosis and a stepwise approach are the keys to improve the quality of life of such patients.
Identifiants
pubmed: 38018802
doi: 10.1097/ICU.0000000000001024
pii: 00055735-990000000-00138
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Steinmetz JD BR, Briant PS, et al. Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health; 2021.
Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf 2017; 15:334–365.
Trattler WB, Majmudar PA, Donnenfeld ED, et al. The Prospective Health Assessment of Cataract Patients’ Ocular Surface (PHACO) study: the effect of dry eye. Clin Ophthalmol 2017; 11:1423–1430.
Gupta PK, Drinkwater OJ, VanDusen KW, et al. Prevalence of ocular surface dysfunction in patients presenting for cataract surgery evaluation. J Cataract Refract Surg 2018; 44:1090–1096.
Yeu E, Koetting C, Calvelli H. Prevalence of meibomian gland atrophy in patients undergoing cataract surgery. Cornea 2023; 42:1355–1359.
Starr CE, Gupta PK, Farid M, et al. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. J Cataract Refract Surg 2019; 45:669–684.
Liu YC, Wilkins M, Kim T, et al. Cataracts. Lancet 2017; 390:600–612.
Li XM, Hu L, Hu J, Wang W. Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery. Cornea 2007; 26: (9 Suppl 1): S16–S20.
Kasetsuwan N, Satitpitakul V, Changul T, Jariyakosol S. Incidence and pattern of dry eye after cataract surgery. PLoS One 2013; 8:e78657.
Han KE, Yoon SC, Ahn JM, et al. Evaluation of dry eye and meibomian gland dysfunction after cataract surgery. Am J Ophthalmol 2014; 157:1144–1150. e1.
Oh T, Jung Y, Chang D, et al. Changes in the tear film and ocular surface after cataract surgery. Jpn J Ophthalmol 2012; 56:113–118.
Iglesias E, Sajnani R, Levitt RC, et al. Epidemiology of persistent dry eye-like symptoms after cataract surgery. Cornea 2018; 37:893–898.
Choi YJ, Park SY, Jun I, et al. Perioperative ocular parameters associated with persistent dry eye symptoms after cataract surgery. Cornea 2018; 37:734–739.
Villani E, Catania AG, Luccarelli SV, et al. Dry eye and cataract surgery: narrative review and recommendations for management. Eur J Ophthalmol 2023; doi: 10.1177/11206721231174060. [Online ahead of print].
doi: 10.1177/11206721231174060.
Priyadarshini K, Sharma N, Kaur M, Titiyal JS. Cataract surgery in ocular surface disease. Indian J Ophthalmol 2023; 71:1167–1175.
Agarwal S, Srinivasan B, Harwani AA, et al. Perioperative nuances of cataract surgery in ocular surface disorders. Indian J Ophthalmol 2022; 70:3455–3464.
Sangwan VS, Burman S. Cataract surgery in Stevens-Johnson syndrome. J Cataract Refract Surg 2005; 31:860–862.
Movahedan A, Djalilian AR. Cataract surgery in the face of ocular surface disease. Curr Opin Ophthalmol 2012; 23:68–72.
Chuang J, Shih KC, Chan TC, et al. Preoperative optimization of ocular surface disease before cataract surgery. J Cataract Refract Surg 2017; 43:1596–1607.
Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006; 25:900–907.
Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf 2017; 15:276–283.
Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II Diagnostic Methodology report. Ocul Surf 2017; 15:539–574.
Blackie CA, Korb DR, Knop E, et al. Nonobvious obstructive meibomian gland dysfunction. Cornea 2010; 29:1333–1345.
Kim J. The use of vital dyes in corneal disease. Curr Opin Ophthalmol 2000; 11:241–247.
Dua HS. The conjunctiva in corneal epithelial wound healing. Br J Ophthalmol 1998; 82:1407–1411.
Cheung AY, Sarnicola E, Denny MR, et al. Limbal stem cell deficiency: demographics and clinical characteristics of a large retrospective series at a single tertiary referral center. Cornea 2021; 40:1525–1531.
Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 2011; 151:792–798. e1.
Goerlitz-Jessen MF, Gupta PK, Kim T. Impact of epithelial basement membrane dystrophy and Salzmann nodular degeneration on biometry measurements. J Cataract Refract Surg 2019; 45:1119–1123.
Errais K, Bouden J, Mili-Boussen I, et al. Effect of pterygium surgery on corneal topography. Eur J Ophthalmol 2008; 18:177–181.
Tomidokoro A, Miyata K, Sakaguchi Y, et al. Effects of pterygium on corneal spherical power and astigmatism. Ophthalmology 2000; 107:1568–1571.
Hay EA, Knowles C, Kolb A, MacKenzie A. Using the CRISPR/Cas9 system to understand neuropeptide biology and regulation. Neuropeptides 2016; 64:19–25.
Serin D, Karsloğlu S, Kyan A, Alagöz G. A simple approach to the repeatability of the Schirmer test without anesthesia: eyes open or closed? Cornea 2007; 26:903–906.
Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf 2017; 15:575–628.
Amescua G, Akpek EK, Farid M, et al. Blepharitis Preferred Practice Pattern®. Ophthalmology 2019; 126:56–93.
Sarnicola C, Sarnicola E, Panico E, et al. Cataract surgery in corneal transplantation. Curr Opin Ophthalmol 2020; 31:23–27.
Sarnicola V, Toro P, Sarnicola C, et al. Long-term graft survival in deep anterior lamellar keratoplasty. Cornea 2012; 31:621–626.
Sarnicola E, Sarnicola C, Cheung AY, et al. Surgical corneal anatomy in deep anterior lamellar keratoplasty: suggestion of new acronyms. Cornea 2019; 38:515–522.
Reinhart WJ, Musch DC, Jacobs DS, et al. Deep anterior lamellar keratoplasty as an alternative to penetrating keratoplasty a report by the american academy of ophthalmology. Ophthalmology 2011; 118:209–218.
Wilson SE. Topical losartan: practical guidance for clinical trials in the prevention and treatment of corneal scarring fibrosis and other eye diseases and disorders. J Ocul Pharmacol Ther 2023; 39:191–206.
Sampaio LP, Hilgert GSL, Shiju TM, et al. Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after Descemet's membrane-endothelial excision in rabbits. Exp Eye Res 2022; 216:108940.
Sampaio LP, Hilgert GSL, Shiju TM, et al. Topical losartan and corticosteroid additively inhibit corneal stromal myofibroblast generation and scarring fibrosis after alkali burn injury. Transl Vis Sci Technol 2022; 11:9.
Sampaio LP, Hilgert GSL, Shiju TM, et al. Losartan inhibition of myofibroblast generation and late haze (scarring fibrosis) after PRK in rabbits. J Refract Surg 2022; 38:820–829.
Pereira-Souza AL, Ambrósio R, Bandeira F, et al. Topical losartan for treating corneal fibrosis (haze): first clinical Experience. J Refract Surg 2022; 38:741–746.
Sotozono C, Ang LP, Koizumi N, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology 2007; 114:1294–1302.
Saw VP, Dart JK. Ocular mucous membrane pemphigoid: diagnosis and management strategies. Ocul Surf 2008; 6:128–142.
Cheung AY, Eslani M, Kurji KH, et al. Long-term outcomes of living-related conjunctival limbal allograft compared with keratolimbal allograft in patients with limbal stem cell deficiency. Cornea 2020; 39:980–985.
Sangwan VS, Gupta S, Das S. Cataract surgery in ocular surface diseases: clinical challenges and outcomes. Curr Opin Ophthalmol 2018; 29:81–87.
Neumann R, Tauber J, Foster CS. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology 1991; 98:858–862.
Puranik CJ, Murthy SI, Taneja M, Sangwan VS. Outcomes of cataract surgery in ocular cicatricial pemphigoid. Ocul Immunol Inflamm 2013; 21:449–454.
Vasavada AR, Dholakia SA. Phacoemulsification in total white cataract with Stevens-Johnson syndrome. Indian J Ophthalmol 2007; 55:146–148.
Narang P, Mohamed A, Mittal V, Sangwan VS. Cataract surgery in chronic Stevens-Johnson syndrome: aspects and outcomes. Br J Ophthalmol 2016; 100:1542–1546.
Sharma N, Aron N, Venugopal R, et al. New surgical approach in cases of cataract with ocular Stevens-Johnson syndrome. J Cataract Refract Surg 2016; 42:1549–1555.
Geerling G, Dart JK. Management and outcome of cataract surgery in ocular cicatricial pemphigoid. Graefes Arch Clin Exp Ophthalmol 2000; 238:112–118.
Das S, Mohamed A, Sangwan VS. Clinical course and outcomes in patients with Mooren ulcer who had cataract surgery. J Cataract Refract Surg 2017; 43:1044–1049.
Sangwan VS, Surender P, Burman S. Cataract surgery in patients with Mooren's ulcer. J Cataract Refract Surg 2005; 31:359–362.
Ashar JN, Mathur A, Sangwan VS. Immunosuppression for Mooren's ulcer: evaluation of the stepladder approach--topical, oral and intravenous immunosuppressive agents. Br J Ophthalmol 2013; 97:1391–1394.
Eslani M, Cheung AY, Kurji K, et al. Long-term outcomes of conjunctival limbal autograft in patients with unilateral total limbal stem cell deficiency. Ocul Surf 2019; 17:670–674.
Cheung AY, Sarnicola E, Kurji KH, et al. Cincinnati protocol for preoperative screening and donor selection for ocular surface stem cell transplantation. Cornea 2018; 37:1192–1197.
Cheung AY, Jeffrey JH, Govil A, et al. Allograft ocular surface stem cell transplantation outcomes with decreased or no systemic immunosuppression in the elderly. Cornea 2023.
Movahedan A, Cheung AY, Eslani M, et al. Long-term outcomes of ocular surface stem cell allograft transplantation. Am J Ophthalmol 2017; 184:97–107.
Kim BY, Riaz KM, Bakhtiari P, et al. Medically reversible limbal stem cell disease: clinical features and management strategies. Ophthalmology 2014; 121:2053–2058.
Holland EJ. Management of limbal stem cell deficiency: a historical perspective, past present, and future. Cornea 2015; 34: (Suppl 10): S9–S15.
Djalilian AR, Holland EJ, Schwartz GS. Limbal stem cell deficiency. Ophthalmology 2003; 110:2071 author reply -2.
Deng SX, Kruse F, Gomes JAP, et al. Global consensus on the management of limbal stem cell deficiency. Cornea 2020; 39:1291–1302.
Yu Y, Hua H, Wu M, et al. Evaluation of dry eye after femtosecond laser-assisted cataract surgery. J Cataract Refract Surg 2015; 41:2614–2623.
Shao D, Zhu X, Sun W, et al. Effects of femtosecond laser-assisted cataract surgery on dry eye. Exp Ther Med 2018; 16:5073–5078.
Lin HY, Lin TY, Chuang YJ, et al. A novel sequential docking technique: use of femtosecond arcuate keratotomy and femtosecond assisted cataract surgery using a pupil expansion ring on a patient with intraoperative Floppy iris syndrome. Int Med Case Rep J 2020; 13:139–144.
Cabourne E, Lau N, Flanagan D, et al. Severe corneal melting after cataract surgery in patients prescribed topical postoperative NSAIDs and dexamethasone/neomycin combination therapy. J Cataract Refract Surg 2020; 46:138–142.
Tu PN, Hou YC. Bilateral corneal melting associated with topical diclofenac 0.1% after cataract surgery in a patient with Sjögren's syndrome. Taiwan J Ophthalmol 2019; 9:202–205.
Rigas B, Huang W, Honkanen R. NSAID-induced corneal melt: clinical importance, pathogenesis, and risk mitigation. Surv Ophthalmol 2020; 65:1–11.